New England Research & Management Inc. Has $732,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

New England Research & Management Inc. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 23.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,355 shares of the company’s stock after selling 425 shares during the quarter. New England Research & Management Inc.’s holdings in IDEXX Laboratories were worth $732,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gotham Asset Management LLC boosted its holdings in shares of IDEXX Laboratories by 79.9% during the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock worth $7,620,000 after purchasing an additional 7,741 shares during the period. Brevan Howard Capital Management LP acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $3,183,000. Assenagon Asset Management S.A. boosted its holdings in shares of IDEXX Laboratories by 25.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after purchasing an additional 8,831 shares during the period. Carderock Capital Management Inc. boosted its holdings in shares of IDEXX Laboratories by 35.7% during the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after purchasing an additional 4,315 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its holdings in shares of IDEXX Laboratories by 9.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 42,045 shares of the company’s stock worth $23,307,000 after purchasing an additional 3,627 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research reports. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Barclays reduced their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $586.63.

IDEXX Laboratories Trading Down 1.4 %

Shares of IDXX stock opened at $487.20 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The firm’s fifty day simple moving average is $501.58 and its 200 day simple moving average is $526.94. The firm has a market capitalization of $40.24 billion, a P/E ratio of 47.16, a price-to-earnings-growth ratio of 4.03 and a beta of 1.33. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The business had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the sale, the director now owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.